Here, we found that the most significant correlations with both PHGDH and FKBP9 were found for AZD2014 (Fig. 6e), suggesting that AZD2014 might be a promising targeted therapy for the aggressive IDH wild-type GBM subtype. This evidence concerns the gene FKBP9 and glioblastoma.